SBPs offer a potential strategy for managing gout, a prevalent inflammatory arthritis affecting millions worldwide [73] and leading to chronic disability if left untreated [74], by directly inhibiting the pivotal enzyme xanthine oxidase (XO). The gene discussed is XDH; the disease is gout.